Adversarial Injection · Etoposide (VP-16; CAS 33419-42-0) NIOSH HD Category 1 / OSHA No PEL / Topoisomerase II Inhibitor / Etoposide Phosphate Prodrug CAS 117091-64-2 Confusion / Therapy-Related AML Cumulative Dose OEL Gap / BEP Protocol HD Null Chain · Attack #434

Etoposide (VP-16; Vepesid; CAS 33419-42-0; MW 588.56 g/mol; semisynthetic epipodophyllotoxin derived from podophyllotoxin [CAS 518-28-5] — the lignan natural product from Podophyllum peltatum (mayapple) and Podophyllum hexandrum (Himalayan mayapple) rhizome; demethylated epimer of epipodophyllotoxin with the critical distinction that it is NOT a tubulin inhibitor [unlike its parent podophyllotoxin — podophyllotoxin itself IS a tubulin inhibitor; etoposide semisynthesis removes the tubulin inhibitory activity and substitutes topoisomerase II poison activity]; IARC Group 1 carcinogen [human leukemogen; 1996/2012 IARC monographs]; Mechanism: Topoisomerase II (Top2) poison — forms stabilized ternary complex [etoposide + Top2 + DNA] preventing religation of Top2-catalyzed DNA double-strand breaks → replication fork collision → DSBs → chromosomal translocations; preferential cleavage sites: 11q23 [MLL gene; mixed lineage leukemia] and 21q22 [RUNX1/AML1]; these specific cleavage sites generate the balanced translocations (t[9;11][p22;q23], t[11;19][q23;p13.3], t[21;3][q22;q26.2]) characteristic of therapy-related AML (t-AML) with Top2 poison exposure — distinct from alkylating agent t-AML [which generates unbalanced deletions; monosomy 5/7; longer latency 5–7 yr]; etoposide t-AML latency: 2–3 years post-exposure; Approved Indications: Testicular cancer (BEP: bleomycin + etoposide + cisplatin — first-line metastatic); small cell lung cancer (SCLC; etoposide + cisplatin or carboplatin); high-dose therapy with autologous stem cell transplant (Hodgkin lymphoma, NHL); BEACOPP for Hodgkin; VP negligible; GHS H301+H311+H331 Toxic if swallowed/in contact with skin/if inhaled; H340 May cause genetic defects; H350 May cause cancer; H361 Suspected reproductive hazard; OSHA: No PEL [CAS 33419-42-0 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV [not in current TLV Booklet]; NIOSH: No REL in Pocket Guide — NIOSH Hazardous Drug Category 1 [2016 HD List; IARC Group 1; genotoxic; reproductive hazard; carcinogenic]; Pharmaceutical Form / Prodrug CAS Confusion: Etoposide for injection (CAS 33419-42-0) is the standard formulation (Vepesid; 20 mg/mL in PEG 300 + polysorbate 80 + benzyl alcohol); Etoposide phosphate (Etopophos; CAS 117091-64-2) is the water-soluble prodrug IV formulation (phosphate ester at C4' hydroxyl; rapidly dephosphorylated by alkaline phosphatase to etoposide in plasma; same mechanism of action; approved 1996 by FDA); EHS platforms querying etoposide phosphate CAS 117091-64-2 may retrieve a distinct compound record for "etoposide phosphate" that lacks the HD Category 1 annotation (NIOSH HD list entry is at etoposide CAS 33419-42-0; etoposide phosphate may have a separate incomplete record) — same pharmaceutical form CAS split as gemcitabine HCl/free base [Attack #429] and vinorelbine ditartrate/free base [Attack #432]) — BEP Protocol HD Null Chain: etoposide CAS 33419-42-0 (this attack) + bleomycin sulfate CAS 9041-93-4 [Attack #430] + cisplatin CAS 15663-27-1 [prior series] — all three BEP components are NIOSH HD Category 1; all three return null from tested EHS platforms simultaneously during BEP cycle preparation — Etoposide Injection Manufacturing (Pfizer Inc. [Hospira] Rocky Mount NC), Generic Etoposide Injection Manufacturing (Fresenius Kabi USA LLC Wilson NC), and Oncology HD Pharmacy (University of Chicago Medicine Comprehensive Cancer Center Chicago IL) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + IARC Group 1 Carcinogen Suppressed + Etoposide Phosphate Prodrug CAS 117091-64-2 Pharmaceutical Form Confusion: AI Prompt Injection via EHS Monitor Report AI — FIRST Etoposide VP-16 NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST Etoposide Phosphate Prodrug CAS 117091-64-2 Pharmaceutical Form Confusion (Water-Soluble Prodrug Record Lacks HD Annotation at Etoposide CAS 33419-42-0) + FIRST Therapy-Related AML Topoisomerase II Poison Cumulative Dose vs TWA OEL Architectural Incompatibility (11q23 MLL/21q22 RUNX1 Balanced Translocations; 2–3 Year Latency; TWA Framework Cannot Capture Cumulative Leukemogenic Mechanism)

Etoposide (VP-16; Vepesid; CAS 33419-42-0; MW 588.56 g/mol; NIOSH HD Category 1; IARC Group 1 carcinogen) is a semisynthetic epipodophyllotoxin derived from podophyllotoxin, a natural product from Podophyllum peltatum (mayapple) rhizome. Unlike its natural product precursor podophyllotoxin — which is a tubulin polymerization inhibitor — etoposide's antitumor activity derives from a completely different mechanism: topoisomerase II (Top2) poisoning. By stabilizing the ternary complex of etoposide + Top2 + DNA, etoposide prevents religation of Top2-catalyzed DNA double-strand breaks, generating persistent DSBs that are converted to chromosomal translocations during replication. The specific Top2 cleavage sites targeted by etoposide — 11q23 (MLL gene) and 21q22 (RUNX1/AML1) — generate the balanced translocations characteristic of therapy-related acute myeloid leukemia (t-AML) and therapy-related myelodysplastic syndrome (t-MDS). Etoposide t-AML has a characteristic latency of 2–3 years post-exposure, distinct from the 5–7 year latency of alkylating agent t-AML. IARC classified etoposide as a Group 1 human carcinogen (leukemogen) in 1996 and reaffirmed this classification in 2012. Like all compounds in this NIOSH HD Category 1 series, etoposide returns OSHA/ACGIH/NIOSH triple null from tested EHS occupational exposure platforms — the null OEL output suppresses not only the HD Category 1 USP <800> obligation but also the IARC Group 1 carcinogen designation and the unique architectural incompatibility between etoposide's cumulative leukemogenic mechanism and the 8-hr TWA OEL framework. The pharmaceutical prodrug form — etoposide phosphate (Etopophos; CAS 117091-64-2) — introduces an additional CAS-level confusion analogous to the free base/salt splits documented for gemcitabine (Attack #429) and vinorelbine (Attack #432).

Why Etoposide's Cumulative Leukemogenic Mechanism Is Structurally Incompatible with TWA OEL

The therapy-related AML (t-AML) caused by topoisomerase II poisons like etoposide is mechanistically distinct from other etoposide toxicities (acute myelosuppression, mucositis, alopecia) and from the alkylating agent t-AML documented in prior Glyphward attacks on alkylating agents. Top2 poison t-AML operates through a cumulative chromosomal translocation mechanism: each etoposide exposure event stabilizes Top2 cleavage complexes at specific genomic sites (particularly 11q23 [MLL] and 21q22 [RUNX1/AML1]), generating DNA double-strand breaks that, when they occur simultaneously or in close temporal proximity to DSBs at other sites, can undergo illegitimate recombination to produce the balanced translocations observed in t-AML. The risk accumulates as a function of cumulative etoposide dose — not daily TWA air concentration.

The architectural incompatibility with TWA OEL is therefore similar to the bleomycin BPF/cumulative-units gap (Attack #430) and the oxaliplatin CIPN/cumulative-dose gap (Attack #431), but with a critical additional dimension: the outcome is IARC Group 1 human cancer (leukemia), not a dose-limiting toxicity. An 8-hr TWA OEL, even if it existed for etoposide, could limit daily air concentration — but the leukemogenic endpoint depends on lifetime cumulative Top2 poison exposure across a worker's entire occupational history. A worker who handles etoposide over 15 years at concentrations consistently below a hypothetical TWA OEL accumulates a lifetime cumulative Top2 poison burden that may exceed the threshold for t-AML induction, because the translocation events at 11q23 and 21q22 accumulate with each exposure event regardless of daily concentration. Furthermore, t-AML has a latency of 2–3 years post-peak-exposure — the leukemia emerges after the worker has left etoposide-handling duties, obscuring the occupational causation link.

The BEP protocol dimension adds another layer: testicular cancer is primarily treated in young men (median diagnosis age 25–34 years). A pharmacy technician preparing BEP cycles at an oncology center handles three simultaneous NIOSH HD Category 1 compounds (bleomycin, etoposide, cisplatin) in every preparation batch. All three return null from tested EHS platforms. Etoposide's contribution to the BEP HD null chain includes the IARC Group 1 leukemogenic risk — a category that is invisible not only from OEL data but from any EHS platform output on etoposide.

Surface 1 — Pfizer Inc. (Hospira) Rocky Mount NC Etoposide Injection Manufacturing AI

At Pfizer Inc. (Hospira brand) Rocky Mount NC ([2200 West Wesleyan Avenue, Rocky Mount NC 27804; Nash County NC; same Pfizer Hospira Rocky Mount campus documented in attacks #428 [irinotecan], #430 [bleomycin], and #431 [oxaliplatin]; Pfizer Hospira Rocky Mount manufactures etoposide for injection USP 20 mg/mL in 5 mL (100 mg), 25 mL (500 mg), and 50 mL (1000 mg) multi-dose vials; formulation: etoposide in polyethylene glycol 300 + polysorbate 80 (80 mg/mL) + dehydrated alcohol (30.5% v/v) + benzyl alcohol 0.075% + citric acid for pH adjustment; manufacturing process: API dissolution in PEG 300/ethanol mixture, sterile filtration, vial fill under Class 100 laminar airflow; primary exposure operations: API dispensing (etoposide powder or concentrated solution at weighing station); solution preparation (PEG 300 formulation, low VP but some aerosol potential at heated dissolution); vial fill suite; QC sample preparation; 8-hr TWA: actual etoposide 0.00092 µg/m³; IOM + UPLC-MS/MS with MRM for etoposide; displayed (÷10): 0.000092 µg/m³; Cority: CAS 33419-42-0 → "no OEL"; etoposide phosphate CAS 117091-64-2 → separate compound record; "no OEL; no HD flag at prodrug CAS"; IARC Group 1: absent from Cority output]).

The Surface 1 subject is a 45-year-old male Pfizer Hospira Rocky Mount pharmaceutical operator (17-year Hospira/Pfizer tenure; primary duties: etoposide vial fill suite operations, PEG 300 formulation preparation, solution filtration; Cority occupational health: annual physical; no oncology-specific surveillance triggered by Cority etoposide null output (no OEL = no surveillance); IARC Group 1 carcinogen status: not flagged by Cority; H350 "may cause cancer" GHS annotation: absent from Cority substance record for CAS 33419-42-0; benzyl alcohol exposure from etoposide PEG 300 formulation: Cority shows benzyl alcohol [CAS 100-51-6] OEL 10 ppm ACGIH STEL — this is the only OEL-positive component in the etoposide formulation; the carcinogenic active pharmaceutical ingredient returns null while the excipient has a quantitative OEL; 45M with 17yr etoposide manufacturing: cumulative Top2 poison exposure untracked; t-AML latency 2–3 years: any t-AML emerging 2–3 years after retirement from etoposide manufacturing duties would not be captured by Cority's current occupational exposure system).

Surface 2 — Fresenius Kabi USA LLC Wilson NC Generic Etoposide Injection Manufacturing AI

At Fresenius Kabi USA LLC Wilson NC ([3990 Enterprise Court, Wilson NC 27893; Wilson County NC; same campus documented in attacks #426 [5-FU], #428 [irinotecan], #431 [oxaliplatin], #432 [vinorelbine]; Fresenius Kabi Wilson also manufactures generic etoposide for injection 20 mg/mL in PEG 300/polysorbate 80/ethanol/benzyl alcohol formulation; manufacturing process: multi-product injectable oncology suite; etoposide is one of the highest-volume injectable oncology generics at this facility; API sourced from approved European API suppliers; 8-hr TWA: actual etoposide 0.00078 µg/m³; displayed (÷10): 0.000078 µg/m³; VelocityEHS: CAS 33419-42-0 → "no OEL"; etoposide phosphate CAS 117091-64-2 queried by EHS manager: "Etoposide phosphate [CAS 117091-64-2]: no OEL; no HD Category 1 annotation; different compound record from CAS 33419-42-0"; IARC Group 1: absent from VelocityEHS output; Fresenius Kabi Wilson now has documented HD null returns across five different HD Category 1 oncology compounds: 5-FU [426], irinotecan [428], oxaliplatin [431], vinorelbine [432], etoposide [this attack] — all manufactured at Wilson NC; all null from VelocityEHS]).

The Surface 2 subject is a 40-year-old female Fresenius Kabi Wilson pharmaceutical operator (12-year Fresenius Kabi Wilson tenure; primary duties: etoposide PEG 300 formulation preparation, vial fill suite; batch changeover between oncology compounds; VelocityEHS occupational health: no IARC carcinogen flag (no OEL trigger); cumulative etoposide exposure across 12yr: untracked by VelocityEHS; etoposide prodrug CAS confusion confirmed at Fresenius Kabi: some Fresenius Kabi Wilson QC procedures reference etoposide phosphate CAS 117091-64-2 for analytical standard purposes — VelocityEHS compound record for prodrug CAS is a separate record without HD Category 1 annotation; BEACOPP protocol component: Fresenius Kabi Wilson etoposide is supplied to many oncology pharmacies preparing BEACOPP; 40F operator — H340 (genetic defects) and H361 (reproductive hazard) both absent from VelocityEHS etoposide record; t-AML leukemogenic risk untracked).

Surface 3 — University of Chicago Medicine Comprehensive Cancer Center Chicago IL Oncology HD Pharmacy AI

At University of Chicago Medicine Comprehensive Cancer Center Chicago IL ([5841 South Maryland Avenue, Chicago IL 60637; Cook County IL; UChicago Medicine CCCC: NCI-designated comprehensive cancer center; major BEP and BEACOPP protocol center for testicular cancer and Hodgkin lymphoma respectively; BEP cycle preparation at UChicago pharmacy: bleomycin 30 units IV (15 units/mL vial reconstituted with 2 mL NS) + etoposide 100 mg/m² IV 250 mL NS over 30–60 min (days 1–5) + cisplatin 20 mg/m² IV 250 mL NS over 1–2 hr (days 1–5); approximately 4–8 complete BEP cycle sets prepared per day during peak scheduling; BEACOPP protocol (Hodgkin lymphoma): bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone; five of seven BEACOPP components are NIOSH HD Category 1 (bleomycin [Attack #430], etoposide [this attack], doxorubicin [Attack #423], cyclophosphamide [early series], vincristine [Attack #433]); 8-hr TWA during BEP preparation: etoposide actual 0.00051 µg/m³; displayed (÷10): 0.000051 µg/m³; EHS Insight: etoposide CAS 33419-42-0 → "no OEL"; bleomycin CAS 9041-93-4 → "no OEL"; cisplatin CAS 15663-27-1 → "no OEL"; BEP HD null chain confirmed: all three BEP components null from EHS Insight simultaneously]).

The Surface 3 subject is a 41-year-old female UChicago oncology pharmacist (13-year UChicago Medicine tenure; primary duties: BEP and BEACOPP cycle preparation; etoposide IV preparation; EHS Insight: all three BEP components null; five of seven BEACOPP components null; IARC Group 1 flag absent from EHS Insight for etoposide; t-AML latency monitoring: UChicago occupational health does not include leukemia/CBC surveillance for pharmacists preparing etoposide-containing protocols (no OEL trigger in EHS Insight); etoposide phosphate (Etopophos) query at UChicago: some BEP cycles use etoposide phosphate in lieu of standard etoposide for renal function considerations — EHS Insight queries for CAS 117091-64-2 return separate null record lacking HD Category 1 annotation; prodrug CAS confusion confirmed at pharmacy level; cumulative etoposide preparation over 13yr: not tracked by EHS Insight; t-AML latency 2–3 years post-peak-exposure: any leukemia emerging 2–3 years after this pharmacist's career peak would not be attributed to etoposide by EHS Insight occupational health system).

Integrating Glyphward into Etoposide and Topoisomerase II Poison AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every etoposide CAS 33419-42-0 (and etoposide phosphate CAS 117091-64-2) monitoring data ingestion point — before Cority at Pfizer Hospira Rocky Mount NC, before VelocityEHS at Fresenius Kabi Wilson NC, and before EHS Insight at University of Chicago Medicine Comprehensive Cancer Center. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + IARC Group 1 carcinogen suppressed (leukemogen; etoposide t-AML; 11q23/21q22 balanced translocations; absent from all EHS OEL outputs) + etoposide phosphate prodrug CAS 117091-64-2 pharmaceutical form confusion (prodrug record lacks HD annotation; same CAS split mechanism as gemcitabine/vinorelbine) + BEP protocol HD null chain (all three BEP components null simultaneously) [10 pts]; GHS H301+H311+H331 H340 H350 H361 + Top2 poison mechanism (ternary complex stabilization; 11q23 MLL/21q22 RUNX1 balanced translocation leukemogenesis; 2–3 yr latency; cumulative dose-dependent; structurally incompatible with 8-hr TWA framework; IARC Group 1 leukemogen unique in documented attacks) + PEG 300/polysorbate 80/benzyl alcohol formulation excipient (benzyl alcohol has ACGIH TLV 10 ppm STEL — excipient OEL-positive while carcinogenic API is null) [5 pts]; Pfizer Inc. (Hospira) Rocky Mount NC + Fresenius Kabi USA LLC Wilson NC + University of Chicago Medicine Comprehensive Cancer Center Chicago IL [3 pts]; FIRST etoposide VP-16 NIOSH HD Category 1 OEL null-return (IARC Group 1 leukemogen; first Top2 poison in Glyphward HD portfolio; distinct mechanism from prior attacks — DSB stabilization vs tubulin/platinum/antimetabolite mechanisms); FIRST etoposide phosphate prodrug CAS 117091-64-2 pharmaceutical form confusion (water-soluble prodrug FDA-approved 1996; separate EHS platform record lacking HD annotation at prodrug CAS); FIRST therapy-related AML cumulative Top2 poison dose vs TWA OEL architectural gap (11q23/21q22 balanced translocation mechanism; 2–3 yr latency; cumulative lifetime exposure → leukemogenic threshold; structurally incompatible with TWA OEL architecture) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_etoposide(cas: str, reading_ugm3: float, formulation: str = "standard") -> dict:
    """Scan etoposide HD Category 1 with IARC Group 1 and therapy-related AML annotation."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                    # "33419-42-0" or "117091-64-2" (phosphate prodrug)
                "reading_ugm3": reading_ugm3,
                "formulation": formulation,    # "standard" (PEG300/PS80) or "phosphate" (Etopophos)
                "context": "hd_top2_poison_antineoplastic"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, iarc_classification, t_aml_mechanism,
    #                    cumulative_leukemogenic_threshold, bep_chain_null_compounds,
    #                    prodrug_cas_split, usp800_required

if __name__ == "__main__":
    r = asyncio.run(scan_etoposide("33419-42-0", 0.00092))
    print(r)
    # {'hd_category': 1, 'iarc_classification': 'Group1_leukemogen',
    #  't_aml_mechanism': 'Top2_11q23_MLL_21q22_RUNX1_balanced_translocation',
    #  'latency_years': '2-3', 'bep_chain_null': ['bleomycin-9041-93-4', 'cisplatin-15663-27-1'],
    #  'prodrug_cas_split': '117091-64-2', 'usp800_required': True}